JOHNSON & JOHNSON
JOHNSON & JOHNSON (JNJ) Stock News
The latest JNJ headlines and market coverage — 7 recent stories, updated throughout the day.
- Zacks Investment Research·Neutral
Johnson & Johnson (JNJ) Earnings Expected to Grow: Should You Buy?
Johnson & Johnson is expected to report Q3 2026 earnings of $2.90 per share (up 3.6% YoY) and revenues of $25.37 billion (up 5.8% YoY) on October 13. However, the company's Earnings ESP is -0.01% with a Zacks Rank #3, making it difficult to predict an earnings beat. While JNJ has beaten consensus estimates in all four of the last quarters, recent analyst revisions have turned slightly bearish, suggesting the stock may not be a compelling earnings-beat candidate.
- Zacks Investment Research·Neutral
Johnson & Johnson (JNJ) Increases Yet Falls Behind Market: What Investors Need to Know
Johnson & Johnson stock gained 1.1% to $270.22 but underperformed the S&P 500's 1.14% gain. The company is expected to report Q3 earnings on October 13, 2026, with projected EPS of $2.96 (up 5.71% YoY) and revenue of $25.36 billion (up 5.71% YoY). However, JNJ trades at a premium valuation with a Forward P/E of 23.05 versus the industry average of 15.67, and holds a Zacks Rank of #3 (Hold).
- Zacks Investment Research·
Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio
Johnson & Johnson is highlighted as a compelling dividend investment with a 2.02% yield, outperforming both its industry (1.93%) and the S&P 500 (1.41%). The company has increased its dividend annually over the past 5 years with an average increase of 5.37%, and maintains a sustainable 49% payout ratio. With solid earnings growth projected at 7.41% for 2026, JNJ is rated as a Hold (Zacks Rank #3), making it suitable for income-focused investors seeking stable cash flow from an established healthcare leader.
- Zacks Investment Research·Neutral
Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Johnson & Johnson stock declined 2.22% on September 8, 2026, underperforming the S&P 500's 0.58% loss. The company is expected to report earnings on October 13, 2026, with forecasted EPS of $2.95 (up 5.36% YoY) and revenue of $25.36 billion (up 5.71% YoY). JNJ holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 23.75, trading at a premium to its industry average.
- GlobeNewswire Inc.·
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
Nanobiotix announced promising Part 1 data from the CONVERGE Phase 2 study evaluating JNJ-1900 (NBTXR3), a nanoradioenhancer, in stage 3 inoperable non-small cell lung cancer. Results showed an 85.7% overall response rate and 57.1% complete response rate in 7 patients receiving the treatment combined with concurrent chemoradiotherapy and durvalumab, significantly exceeding the <5% complete response rate of standard care.
- GlobeNewswire Inc.·
NANOBIOTIX ANNONCE LA PRÉSENTATION DE DONNÉES DE LA PREMIÉRE PARTIE DE L’ÉTUDE CLINIQUE RANDOMISÉE DE PHASE 2 EVALUANT JNJ-1900 (NBTXR3) DANS LES CANCERS DU POUMON DE STADE 3 INOPÉRABLE
Nanobiotix announced early results from the Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3), a nanoradioenhancer developed in collaboration with Johnson & Johnson, in patients with stage 3 inoperable non-small cell lung cancer. The study showed promising efficacy with an 85.7% overall response rate and 57.1% complete response rate in 7 patients who completed treatment, compared to less than 5% complete response rates with current standard of care.
- Yahoo Finance·Neutral
Johnson & Johnson (JNJ): Growth Engine at a Value Price